

RATLIFF, MIRIAM, DR.MED., DIPL.-BIOL.

GENERAL INFORMATION



Consultant, Department of Neurosurgery
University Medical Centre Mannheim
Medical Faculty Mannheim Heidelberg University
Theodor-Kutzer-Ufer 1-3
68167 Mannheim

Postdoctoral Fellow
Clinical Cooperation Unit Neurooncology (Prof. Wick, Prof. Winkler)
German Cancer Research Center, DKFZ
69120 Heidelberg

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
1998-2006	Medicine, University of Ulm and Albert-Ludwigs-University Freiburg
2001-2007	Dipl.-Biol. in Neurobiology, University of Ulm

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2016-ongoing	Consultant, Department of Neurosurgery, University Medical Centre Mannheim
2009-2016	Resident, Department of Neurosurgery, Heidelberg University
2007	Dip.-Biol., University of Ulm
2006	Dr.med., Anatomy, Heidelberg University

PROFESSIONAL EXPERIENCE

Year(s)	Education
2012-ongoing	Postdoctoral research fellow, Clinical Cooperation Unit Neurooncology, (CCU, Chair Prof. Wick, Prof. Winkler), DKFZ, Heidelberg
2006-2009	Postdoctoral research fellow, Molecular Genetics, (CCU, Chair Prof.L'Hernault), Emory University

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2019	Psychooncologist (WPO)
	Specialist Palliative Care Medicine in training
currently	Coordinator of student education for the Department of Neurosurgery
currently	physician responsible for sanitation/hygiene
currently	physician responsible for transfusion medicine
currently	substitutional physician responsible for quality management

MEMBERSHIPS

Year(s)	
	Deutsche Gesellschaft für Neurochirurgie (DGNC)
	Neuroonkologischer Arbeitskreis (NOA)
	Deutsche Krebsgesellschaft (DKG)

INVESTIGATOR CLINICAL TRIALS

Year(s)	
	CAR2BRAIN a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

	N ² M ² 2015-002752-27 Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without <i>MGMT</i> promoter methylation: NCT; Neuro Master Match; N ² M ² (NOA-20)
	VAXIMM 2017-003076-31 VXM01-AVE-04-INT - An open-label, Phase I/II; multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment, with or without second surgery
	EORTC-1709-BTG 2017-003908-50 A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

PUBLICATIONS

- 1.) Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression. [Ratliff M](#), Karimian-Jazi K, Hoffmann DC, Rauschenbach L, Simon M, Hai L, Mandelbaum H, Schubert MC, Kessler T, Uhlig S, Azorin DD, Jung E, Osswald M, Solecki G, Maros ME, Venkataramani V, Glas M, Etminan N, Scheffler B, Wick W, Winkler F. *Neuro Oncol.* 2023
- 2.) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T-cells by blood-borne myeloids in brain tumors. Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, [Ratliff M](#), Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. *Cancer Cell.* 2023
- 3.) Autonomic rhythmic activity in glioma networks drives brain tumor growth. Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, Jabali A, Hai L, Kessler T, Azorin D, Weil S, Kourtesakis A, Sievers P, Habel a, Breckwoldt MO, Karremann MA, [Ratliff M](#), Messmer JM, Yng Y, Reyhan E, Wendler S, Löb C, Mayer C, Figarella K, Osswald M, Solecki G, Sahm F, Garaschuk O, Kuner T, Koch P, Schlesner M, Wick W, Winkler F. *Nature* 2022
- 4.) T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells. Lu KH, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, [Ratliff M](#), Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L. *Neurooncol Adv.* 2022 Aug
- 5.) Glioblastoma hijacks neuronal mechanisms for brain invasion. Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wißmann N, Botz M, Soyka SJ, Beretta CA, Pramatarov RL, Fankhauser L, Garofano L, Freudenberg A, Wagner J, Tanev DI, [Ratliff M](#), Xie R, Kessler T, Hoffmann DC, Hai L, Dörflinger Y, Hoppe S, Yabo YA, Golebiewska A, Niclou SP, Sahm F, Lasorella A, Slowik M, Döring L, Iavarone A, Wick W, Kuner T, Winkler F. *Cell.* 2022 Aug
- 6.) Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. [Ratliff M](#), Kim H, Qi H, Kim M, Ku B, Azorin DD, Hausmann D, Khajuria RK, Patel A, Maier E, Cousin L, Ogier A, Sahm F, Etminan N, Bunse L, Winkler F, El-Khoury V, Platten M, Kwon YJ. *Int J Mol Sci.* 2022 Jun
- 7.) Progression Patterns in Non-Contrast-Enhancing Gliomas Support Brain Tumor Responsiveness to Surgical Lesions. Brenner S, Hartzendorf S, Vogt P, Maier E, Etminan N, Jung E, Wick W, Sahm F, Winkler F, [Ratliff M](#). *Pathol Oncol Res.* 2022 May
- 8.) Rapid-CNS²: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. Patel A, Dogan H, Payne A, Krause E, Sievers P, Schoebe N, Schrimpf D, Blume C, Stichel D, Holmes N, Euskirchen P, Hench J, Frank S, Rosenstiel-Goidts V, [Ratliff M](#), Etminan N, Unterberg A, Dieterich C, Herold-Mende C, Pfister SM, Wick W, Loose M, von Deimling A, Sill M, Jones DTW, Schlesner M, Sahm F. *Acta Neuropathol.* 2022 May
- 9.) Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Gegner HM, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, [Ratliff M](#), Schrimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana FJ, von Deimling A, Wick W, Prinz M, Platten M. *Nat Cancer.* 2021 Jul
- 10.) Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. Jung E, Osswald M, [Ratliff M](#), Dogan H, Xie R, Weil S, Hoffmann DC, Kurz FT, Kessler T, Heiland S, von Deimling A, Sahm F, Wick W, Winkler F. *Nat Commun.* 2021 Feb